The treatment of malignant hypertension and hypertensive emergencies. A statement by the AMA committee on hypertension.
D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003981:Diazoxide / Q000627:therapeutic use; D004341:Drug Evaluation; D004630:Emergencies; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D006974:Hypertension, Malignant / Q000188:drug therapy*; D007022:Hypotension / Q000139:chemically induced; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008722:Methods; D008750:Methyldopa / Q000627:therapeutic use; D010425:Pentolinium Tartrate / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D014294:Trimethaphan / Q000627:therapeutic use
D000959:Antihypertensive Agents; D006834:Hydrazines; D008750:Methyldopa; D014294:Trimethaphan; D012110:Reserpine; D010425:Pentolinium Tartrate; D003981:Diazoxide; D010646:Phentolamine